Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 4/20 | 0.48 |
| ▸ | AR | P10275 | 2/20 | 0.40 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | DAGLA | Q9Y4D2 | 3/20 | 0.35 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.35 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.34 |
| ▸ | ATP1A1 | P05023 | 1/20 | 0.34 |
| ▸ | ATP1B1 | P05026 | 1/20 | 0.34 |
| ▸ | ATP1A3 | P13637 | 1/20 | 0.34 |
| ▸ | ATP1B2 | P14415 | 1/20 | 0.34 |
| ▸ | ATP1A2 | P50993 | 1/20 | 0.34 |
| ▸ | ATP1B3 | P54709 | 1/20 | 0.34 |
| ▸ | FXYD2 | P54710 | 1/20 | 0.34 |
| ▸ | ATP1A4 | Q13733 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
| ▸ | DAGLB | Q8NCG7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL508904 | 0.80 | TRPV3 (0.39) | SCN10ASCN9ASCN5A | |
| SCHEMBL17108362 | 0.74 | PPARG (0.52) | — | |
| SCHEMBL17091450 | 0.73 | LMNA (0.50) | — | |
| SCHEMBL21277580 | 0.73 | GSTP1 (0.50) | MCL1 | |
| SCHEMBL5105144 | 0.68 | MRGPRX4 (0.58) | SCN10ASERPINE1MCL1PTGER4 | |
| SCHEMBL509011 | 0.68 | CA1 (0.57) | — | |
| SCHEMBL10447860 | 0.65 | CA1 (0.50) | SCN10A | |
| SCHEMBL1315107 | 0.65 | TSHR (0.46) | — | |
| SCHEMBL21432857 | 0.65 | L3MBTL1 (0.45) | PLA2G10PLA2G2A | |
| SCHEMBL306823 | 0.64 | KIF11 (0.50) | SERPINE1SCN5AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9198913-B2 | Nitroimidazooxazines and their uses in anti-tubercular therapy | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2015-12-01 | — | — | US | disclosed |
| EP-2459571-B1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | GLOBAL ALLIANCE FOR TB DRUG DEV (US) | 2015-03-11 | — | — | EP | disclosed |
| US-20120028973-A1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028973-A1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | NOX5, MT-ND5, NQO1 | SCN10A 4460/4885AR 4094/4885SERPINE1 4278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.